Lyra Therapeutics, Inc.

NasdaqGM:LYRA Stock Report

Market Cap: US$11.7m

Lyra Therapeutics Valuation

Is LYRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LYRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LYRA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYRA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for LYRA?

Key metric: As LYRA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LYRA. This is calculated by dividing LYRA's market cap by their current revenue.
What is LYRA's PS Ratio?
PS Ratio8.1x
SalesUS$1.47m
Market CapUS$11.65m

Price to Sales Ratio vs Peers

How does LYRA's PS Ratio compare to its peers?

The above table shows the PS ratio for LYRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
PULM Pulmatrix
2.2xn/aUS$20.5m
SHWZ Medicine Man Technologies
0.05x6.0%US$8.8m
MRNS Marinus Pharmaceuticals
0.6x34.9%US$17.0m
JAGX Jaguar Health
0.9x34.8%US$9.1m
LYRA Lyra Therapeutics
8.1x61.6%US$11.7m

Price-To-Sales vs Peers: LYRA is expensive based on its Price-To-Sales Ratio (8.1x) compared to the peer average (0.9x).


Price to Sales Ratio vs Industry

How does LYRA's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.79b
PRGO Perrigo
0.8x3.4%US$3.70b
BHC Bausch Health Companies
0.3x1.5%US$3.01b
SNDL SNDL
0.8x7.2%US$520.38m
LYRA 8.1xIndustry Avg. 2.5xNo. of Companies70PS03.67.210.814.418+
70 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LYRA is expensive based on its Price-To-Sales Ratio (8.1x) compared to the US Pharmaceuticals industry average (2.5x).


Price to Sales Ratio vs Fair Ratio

What is LYRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LYRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LYRA's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LYRA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.18
US$1.25
+587.2%
60.0%US$2.00US$0.50n/a2
Nov ’25US$0.26
US$1.25
+382.8%
60.0%US$2.00US$0.50n/a2
Oct ’25US$0.26
US$1.25
+382.6%
60.0%US$2.00US$0.50n/a2
Sep ’25US$0.32
US$4.50
+1,298.8%
103.0%US$11.00US$0.50n/a3
Aug ’25US$0.31
US$4.50
+1,369.1%
103.0%US$11.00US$0.50n/a3
Jul ’25US$0.30
US$4.50
+1,415.7%
103.0%US$11.00US$0.50n/a3
Jun ’25US$0.33
US$4.50
+1,272.0%
103.0%US$11.00US$0.50n/a3
May ’25US$5.25
US$11.60
+121.0%
16.0%US$15.00US$10.00n/a5
Apr ’25US$6.25
US$12.00
+92.0%
13.9%US$15.00US$10.00n/a5
Mar ’25US$5.69
US$12.20
+114.4%
13.1%US$15.00US$10.00n/a5
Feb ’25US$4.59
US$11.80
+157.1%
18.9%US$15.00US$8.00n/a5
Jan ’25US$5.24
US$11.80
+125.2%
18.9%US$15.00US$8.00n/a5
Dec ’24US$3.62
US$12.33
+240.7%
19.1%US$15.00US$8.00n/a6
Nov ’24US$2.95
US$12.67
+329.4%
20.7%US$15.00US$8.00US$0.266
Oct ’24US$3.91
US$12.20
+212.0%
21.6%US$15.00US$8.00US$0.265
Sep ’24US$3.49
US$10.60
+203.7%
34.1%US$15.00US$5.00US$0.325
Aug ’24US$3.28
US$10.75
+227.7%
35.7%US$15.00US$6.00US$0.314
Jul ’24US$4.11
US$10.75
+161.6%
35.7%US$15.00US$6.00US$0.304
Jun ’24US$2.70
US$10.75
+298.1%
35.7%US$15.00US$6.00US$0.334
May ’24US$2.59
US$14.00
+440.5%
23.1%US$18.00US$9.00US$5.254
Apr ’24US$2.01
US$15.20
+656.2%
24.8%US$20.00US$9.00US$6.255
Mar ’24US$2.26
US$16.75
+641.2%
14.2%US$20.00US$14.00US$5.694
Feb ’24US$2.90
US$17.75
+512.1%
22.0%US$24.00US$14.00US$4.594
Jan ’24US$3.14
US$17.75
+465.3%
22.0%US$24.00US$14.00US$5.244
Dec ’23US$3.36
US$17.75
+428.3%
22.0%US$24.00US$14.00US$3.624
Nov ’23US$4.69
US$17.75
+278.5%
22.0%US$24.00US$14.00US$2.954

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies